Form 4: Centessa General Counsel Sells Shares After Option Exercise

Centessa Pharmaceuticals' General Counsel, Iqbal J. Hussain, sold 40,000 ordinary shares in two transactions after exercising options, pursuant to a pre-arranged 10b5-1 trading plan.

Summary

• Iqbal J. Hussain, General Counsel of Centessa Pharmaceuticals plc, reported transactions involving the exercise of stock options and subsequent sale of ordinary shares.
• On September 9, 2025, Hussain acquired 20,000 ordinary shares by exercising options at $5.84 per share and simultaneously sold these 20,000 shares at a weighted average price of $20.0051.
• On September 10, 2025, Hussain acquired another 20,000 ordinary shares by exercising options at $5.84 per share and sold these 20,000 shares at $22.00 per share.
• These sales were conducted under a Rule 10b5-1 trading plan adopted on September 14, 2024.
• Following these transactions, Hussain directly beneficially owns 105,386 ordinary shares and indirectly owns 5,500 shares through a spouse.
• Remaining share options (right to buy) total 239,559 after the exercises.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While insider selling can sometimes be viewed negatively, the fact that these sales were pre-planned under a Rule 10b5-1 plan mitigates concerns about management's immediate outlook. The executive realized significant gains, which is positive for the individual, but the transaction itself doesn't provide strong positive or negative signals for the company's operational performance.

Positives

• The General Counsel realized significant gains by selling shares at prices substantially higher than the exercise price ($20.0051 and $22.00 vs. $5.84).
• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned diversification or liquidity event rather than a reaction to new, undisclosed information.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived by investors as a lack of confidence in the company's future stock price, although this is mitigated by the pre-planned nature.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 14, 2024.
• The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Industry Context

This Form 4 filing reports routine insider transactions for a biotechnology company. Such transactions, particularly when executed under a 10b5-1 plan, are common for executives to manage personal finances and diversify holdings, and do not inherently reflect specific industry trends or competitive positioning.

Comparison to Industry Standards

• Not applicable. This filing details specific insider trading activities and does not provide company performance metrics or project results that can be directly compared to global industry benchmarks or specific comparable companies.

Corporate Governance

Stakeholder Impact

• Shareholders: May view the insider selling as a neutral event due to the 10b5-1 plan, or potentially a slight negative if they interpret it as a lack of strong conviction, though the latter is less likely given the context.
• Management: The General Counsel successfully monetized a portion of his equity compensation, which is a positive for the individual.

Next Steps

• The Reporting Person undertakes to provide full information regarding the number of shares sold at each separate price within the range upon request.
• The remaining 239,559 share options will continue to vest in monthly installments.

Key Dates

Recommendation

This Form 4 filing reports routine insider transactions (option exercise and sale) executed under a pre-arranged 10b5-1 plan. While the General Counsel realized significant gains, these transactions are primarily for personal financial management and do not provide new fundamental information about Centessa Pharmaceuticals' operational performance, strategic direction, or future prospects. Therefore, based solely on this filing, there is no basis to change an existing investment thesis, warranting a 'hold' recommendation.

Keywords

Centessa Pharmaceuticals, CNTA, Insider Trading, Form 4, Stock Options, Share Sale, Iqbal J. Hussain, General Counsel, 10b5-1 Plan, Biotechnology, Pharmaceuticals